The forecasted data for the penicillins and streptomycins in dosage market size per capita in France indicates a slight decline from $11.19 in 2024 to $11.12 by 2028. This represents a decrease of approximately 0.53% over the forecast period. The year-on-year variations show a consistent minimal negative trend. With a compound annual growth rate (CAGR) analysis over five years, a subtle contraction in market value per capita is noted.
Future trends to monitor include potential impacts of regulatory changes, advances in pharmaceutical technology, or shifts in public health policy that may influence penicillins and streptomycins' market demand.
